Vertex Pharmaceuticals Incorporated VRTX stock has risen 15.4% in a month, driven mainly by strong second-quarter results, higher 2026 guidance, growing confidence in its post-cystic fibrosis (CF) growth story and renewed optimism around its renal pipeline.
Vertex reported second-quarter revenues of $3.33 billion, up 12% year over year, and raised its full-year revenue outlook to $13.1-$13.2 billion from $12.95-$13.1 billion previously. Earnings of $4.73 per share rose around 5% year over year.
Let's take a closer look at these factors to assess the key drivers behind VRTX's recent rally and determine how investors should approach the stock after its strong price gain.
Consistent Rise in VRTX’s CF Product Sales
Vertex holds a leadership position in the CF market. With its five CF medicines, Vertex can treat nearly 95% of all people living with CF in core markets. Demand for its CF therapies continues to grow, as the company expands access globally and wins approvals in younger patient populations. Meanwhile, Vertex does not face any near-term headwinds from LOE or increased competition for its CF therapies.
Its CF products generated revenues of $6.1 billion in the first half of 2026, up 8.4% year over year, driven by Trikafta/Kaftrio as well as increasing contribution from Alyftrek, a next-in-class triple combination regimen and Vertex’s fifth and newest CF medicine.
Alyftrek continues to outperform expectations and generated sales worth $573.6 million in the second quarter, up 35% on a sequential basis. The rollout of Alyftrek in the United States and Europe is progressing well across all patient groups. The drug surpassed $1 billion in cumulative global revenues in the first half of 2026. Alyftrek’s once-daily dosing and improved sweat chloride profile continue to resonate with patients and doctors.
Vertex is also conducting studies to expand the labels of Alyftrek and Trikafta to additional mutations as well as to younger patients. Vertex recently began global regulatory filings for Alyftrek in children with cystic fibrosis aged 2 to 5 years.
Vertex expects incremental patients from the label expansions for Alyftrek and Trikafta, along with launches of Alyftrek in additional geographies and for treating younger patients, to drive CF growth through the rest of the year.
VRTX’s New Non-CF Drugs Show Strong Growth Potential
The uptake of Vertex’s newly launched non-CF products, Journavx and Casgevy, was slower than expected in 2025. However, their sales are gradually picking up in 2026.
Journavx, a novel non-opioid pain medicine (suzetrigine), approved last year, has drawn significant investor attention because of the large unmet need for safer pain therapies amid the opioid crisis. Though Journavx’s sales have been slow since launch, its launch metrics and early reimbursement progress look positive. Vertex expects both sales and prescriptions to more than triple in 2026 versus 2025, reflecting the drug’s expanding market access and growing adoption. Journavx generated $49.6 million in sales in the second quarter, up 71% on a sequential basis, backed by strong underlying prescription growth.
Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy, Casgevy, was approved for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), in multiple regions in late 2023/early 2024. Vertex leads the global development and commercialization of Casgevy under the terms of the 2021 agreement with support from CRISPR Therapeutics.
Casgevy’s sales were $76.4 million in the second quarter, up 78% on a sequential basis and 151% on a year-over-year basis due to an increase in patient infusions. Casgevy recorded more than 100 patient initiations in the second quarter as the launch continues to progress. First-half 2026 infusions have already exceeded the total for 2025, supported by improved reimbursement and growing patient uptake across key markets. Vertex is also making rapid progress in the drug’s access and reimbursement. In July, the FDA approved Casgevy for expanded use in pediatric patients 2 years and older with TDT and SCD.
The company expects non-CF products to generate revenues of $500 million plus in 2026, representing year-over-year growth of around 185%, driven by growing Casgevy infusions and a meaningful ramp in Journavx prescriptions and revenues.
Vertex’s Expanding Renal Pipeline Could Diversify Growth
While Vertex’s main focus is on the development and strengthening of its CF franchise, the company also has a rapidly advancing mid - to late-stage pipeline in other disease areas beyond CF, like acute and neuropathic pain, APOL1-mediated kidney disease (AMKD), IgA nephropathy (IgAN), primary membranous nephropathy (pMN) and autosomal dominant polycystic kidney disease (ADPKD).
Many of these candidates represent multibillion-dollar opportunities. Many of these programs are in pivotal development, setting the stage for several potential regulatory filings in 2026 and early 2027, and potential new drug approvals in a couple of years.
Vertex’s candidates for kidney diseases are capturing investor attention. In kidney diseases, key pipeline candidates are VX-407 for ADPKD, inaxaplin for AMKD and povetacicept for IgAN and pMN. It is believed that povetacicept and inaxaplin represent significant commercial opportunities.
Povetacicept was added to Vertex’s portfolio from the Alpine acquisition in 2024. Vertex believes povetacicept has pipeline-in-a-product potential for B-cell-mediated diseases. Povetacicept is designed to target two proteins, namely BAFF and APRIL, which are jointly responsible for the cause of multiple serious autoimmune diseases. In June 2026, the FDA accepted the regulatory filing seeking approval for povetacicept for IgAN. A final decision from the FDA is expected on Nov. 30, 2026. If approved, povetacicept would become Vertex's first commercialized nephrology product. Positive commercial progress of a competitor, Otsuka's IgAN therapy Voyxact, launched in 2025, has increased investor confidence in the IgAN market’s commercial opportunities.
Vertex is also conducting a pivotal phase II/III study of povetacicept for a second potential renal indication, pMN. Vertex is also conducting a phase II study on povetacicept for the treatment of gMG.
Vertex expects its kidney portfolio to become a significant growth driver over the next several years and diversify the company’s revenue streams.
However, Vertex has faced regular pipeline setbacks. In 2026, Vertex ended the phase I/II clinical study on mRNA therapeutic VX-522 in CF, after observing persistent tolerability issues in the study. Vertex was developing VX-522 in partnership with Moderna MRNA.
VRTX’s Price, Valuation and Estimates
Vertex stock has risen 22.0% so far this year, outperforming the industry’s 17.9% growth.
VRTX Stock Outperforms Industry
From a valuation standpoint, Vertex is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 27.52 forward earnings, higher than 19.44 for the industry. The stock is also trading above its five-year mean of 25.23.
VRTX Stock Valuation
The Zacks Consensus Estimate for 2026 earnings has declined from $19.17 per share to $19.01 over the past 30 days, while that for 2027 has deteriorated from $20.97 per share to $20.66 per share over the same time frame.
VRTX Estimate Movement
Stay Invested in VRTX Stock
The company has its share of headwinds like heavy dependence on the CF franchise, regular pipeline setbacks, intensifying competition as well as the risky nature of its non-CF pipeline programs.
However, Vertex dominates the CF market with drugs like Trikafta/Alyftrek and boasts a breakthrough non-CF pipeline. Vertex’s investment case has strengthened materially because the company is gradually transitioning from being predominantly a CF story toward a multi-pillar growth company.
In July 2026, Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, gaining Palsonify, its once-daily oral treatment for acromegaly. The acquisition will further diversify Vertex’s portfolio, adding rare endocrine diseases, which have high unmet need, as its fifth pillar. Vertex believes that Crinetics’ two lead assets, Palsonify and lead pipeline candidate atumelnant, together represent a peak sales opportunity of about $5 billion.
We believe Vertex is a good stock to have in one’s portfolio, considering its strong overall financial performance and robust pipeline progress. Vertex faces minimal competition in the CF franchise, which gives it pricing power. Vertex expects that both Casgevy and Journavx can become multibillion-dollar products in the long term. Long-term investors may retain this Zacks Rank #3 (Hold) stock for now. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Moderna, Inc. (MRNA): Free Stock Analysis Report
CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).